COMPARE · Reviewed July 29, 2026
HALO vs HRMY
Verdict: Side-by-side breakdown using the Bull Rankings model. HALO scored 81.3, HRMY scored 85.1 — HRMY leads.
Compare another set
HALO
Halozyme Therapeutics, Inc.
81.3
$83.28 · $9.9B
fundamentals as of
Score gap
3.8
HRMY leads
HRMY
Harmony Biosciences Holdings, Inc.
85.1
$35.86 · $2.1B
fundamentals as of
The model, pillar by pillar (0–100 each)
HALO
stronger →← stronger
HRMY
81
Qualityreturns · margins · balance sheet
77
100
Growthrevenue & earnings expansion
100
66
Valuevaluation vs sector peers
80
HALO and HRMY split the three pillars evenly.
Fundamentals, head-to-head
HALO
HRMY
$668mC+
FCF
$342mC
+39.1%A
Rev
+20.7%A-
9.91D
D/E
0.18B+
29.2xB
P/E
14.5xA-
0.78A-
PEG
0.67A-
Winner per row is the stronger grade in our model; a tie or a missing value shows no highlight.
Valuation · DCF cross-check
HALO
HRMY
43% below
Price vs fair valuelower is cheaper
75% below
~0%/yr
Growth the price implies10-yr FCF · lower = less priced in
~-19%/yr
+37%
1-yr DCF upside
+208%
+76%
5-yr DCF upside
+306%
+158%
10-yr DCF upside
+509%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
HALO
Why this score
- Buying back stock
- Durable high returns
HRMY
Why this score
- Durable high returns
The companies
HALOHalozyme Therapeutics, Inc.
Why now
Biotechnology · market cap $9.9b. Trading near 52-week high of $84.44 — momentum setup, limited technical margin of safety. Revenue growing +39% — in hypergrowth territory. PEG 0.78 — paying under fair value for the growth rate. 9 sell-side analysts rate this a Buy with a mean 1-yr target of $86.89 (implying +4% upside).
Moat
Net margin 23% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. FCF converts 191% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
D/E 9.91 is elevated — limits strategic flexibility and raises refinancing exposure if rates stay higher for longer. Trading within 1% of the 52-week high — limited technical margin of safety; a momentum reversal would test conviction. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
HRMYHarmony Biosciences Holdings, Inc.
Why now
Biotechnology · market cap $2.1b. 12% off the 52-week high of $40.87. Revenue growing +21%, comfortably above the S&P median. PEG 0.67 — paying under fair value for the growth rate. 10 sell-side analysts rate this a Buy with a mean 1-yr target of $45.40 (implying +27% upside).
Moat
Net margin 16% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 16% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. Free cash flow runs well ahead of reported net income — non-cash charges (depreciation, intangible amortization) are holding down GAAP earnings while cash generation stays strong.
Risk
Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.